The Food and Drug Administration (FDA) is publishing a list of premarket approval applications (PMAs) that have been approved. This list is intended to inform the public of the availability of safety and effectiveness summaries of approved PMAs through the Internet and the Agency's Division of Dockets Management.
Submit written requests for copies of summaries of safety and effectiveness data to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Please cite the appropriate docket number as listed in table 1 of this document when submitting a written request. See the SUPPLEMENTARY INFORMATION section for electronic access to the summaries of safety and effectiveness.
FOR FURTHER INFORMATION CONTACT:
Nicole Wolanski, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 1650, Silver Spring, MD 20993-0002, (301) 796-6570.
In accordance with section 515(d)(4) and (e)(2) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360e(d)(4) and (e)(2)), notification of an order approving, denying, or withdrawing approval of a PMA will continue to include a notice of opportunity to request review of the order under section 515(g) of the FD&C Act. The 30-day period for requesting reconsideration of an FDA action under § 10.33(b) (21 CFR 10.33(b)) for notices announcing approval of a PMA begins on the day the notice is placed on the Internet. Section 10.33(b) provides that FDA may, for good cause, extend this 30-day period. Reconsideration of a denial or withdrawal of approval of a PMA may be sought only by the applicant; in these cases, the 30-day period will begin when the applicant is notified by FDA in writing of its decision.
The regulations provide that FDA publish a quarterly list of available safety and effectiveness summaries of PMA approvals and denials that were announced during that quarter. The following is a list of approved PMAs for which summaries of safety and effectiveness were placed on the Internet from July 1, 2011, through September 30, 2011. There were no denial actions during this period. The list provides the manufacturer's name, the product's generic name or the trade name, and the approval date.
Table 1—List of Safety and Effectiveness Summaries for Approved PMAs Made Available From July 1, 2011, Through September 30, 2011
|PMA No. Docket No.||Applicant||Trade name||Approval date|
|P100031, FDA-2011-M-0502||Roche Diagnostics Corp.||ELECSYS ANTI-HBC IMMUNOASSAY & ELECSYS PRECICONTROL ANTI-HBC||June 22, 2011.|
|P100032, FDA-2011-M-0503||Roche Diagnostics Corp.||ELECSYS ANTI-HBC IMMUNOASSAY, ELECSYS PRECICONTROL ANTI-HBC FOR USE ON THE ELECSYS 2010 IMMUNOASSAY ANALYZER||June 27, 2011.|
|P100001, FDA-2011-M-0563||Ortho-Clinical Diagnostics, Inc.||VITROS IMMUNODIAGNOSTICS PRODUCTS ANTI-HBE REAGENT PACK, VITROS IMMUNODIAGNOSTIC PRODUCTS ANTI-HBE CALIBRATOR, AND VITROS IMMUNODIAGNOSTIC PRODUCTS ANTI-HBE CONTROLS||July 20, 2011.|
|P110001, FDA-2011-M-0564||Abbott Vascular||RX HERCULINK ELITE RENAL STENT SYSTEM||July 20, 2011.|
|P100044, FDA-2011-M-0600||Intersect ENT||PROPEL||August 11, 2011.|
|P110020, FDA-2011-M-0601||Roche Molecular Systems, Inc.||COBAS 4800 BRAF V600 MUTATION TEST||August 17, 2011.|
|P110012, FDA-2011-M-0630||Abbott Molecular, Inc.||VYSIS ALK BREAK APART FISH PROBE KIT; VYSIS PARAFFIN PRETREATMENT IV & POST HYBRIDIZATION WASH BUFFER KIT; PROBECHEK ALK NEGATIVE CONTROL SLIDES; AND PROBECHEK ALK POSITIVE CONTROL SLIDES||August 26, 2011.|
|H100006, FDA-2011-M-0707||Synapse Biomedical, Inc.||NEURX DPS DIAPHRAGM PACING SYSTEM||September 28, 2011.|
II. Electronic Access
Persons with access to the Internet may obtain the documents at http://www.fda.gov/cdrh/pmapage.html.
Dated: January 9, 2012.
Acting Assistant Commissioner for Policy.
[FR Doc. 2012-537 Filed 1-12-12; 8:45 am]
BILLING CODE 4160-01-P